ストックスクリーナーアプリを入手
38.04
2.95%
1.09
アフターアワーズ：
37.86
-0.18
-0.47%
前日終値:
$36.95
開ける：
$37.47
24時間の取引高:
1.84M
Relative Volume:
0.93
時価総額：
$3.29B
収益：
$170.10M
当期純損益:
$-239.59M
株価収益率:
-13.59
EPS:
-2.8
ネットキャッシュフロー:
$-191.20M
1週間 パフォーマンス:
+1.25%
1か月 パフォーマンス:
-0.55%
6か月 パフォーマンス:
-25.76%
1年 パフォーマンス:
-33.44%
1日の値動き範囲:
$36.08
$38.15
1週間の範囲:
$35.38
$38.34
52週間の値動き範囲:
$30.04
$67.88
Crispr Therapeutics Ag Stock (CRSP) Company Profile
CRSP を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CRSP
Crispr Therapeutics Ag
|
38.04 | 3.24B | 170.10M | -239.59M | -191.20M | -2.80 |
|
ONC
Beone Medicines Ltd Adr
|
251.72 | 25.76B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
446.48 | 114.53B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.3401 | 40.54M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
84.81 | 6.44B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
487.86 | 65.13B | 14.09B | 4.50B | 2.96B | 39.28 |
Crispr Therapeutics Ag Stock (CRSP) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-02-14 | アップグレード | Evercore ISI | In-line → Outperform |
| 2025-02-12 | アップグレード | TD Cowen | Sell → Hold |
| 2025-02-03 | 開始されました | H.C. Wainwright | Buy |
| 2024-08-06 | 繰り返されました | Needham | Buy |
| 2024-08-02 | 開始されました | Rodman & Renshaw | Buy |
| 2024-06-28 | 再開されました | Guggenheim | Neutral |
| 2024-02-15 | 開始されました | Wolfe Research | Peer Perform |
| 2023-12-11 | ダウングレード | TD Cowen | Market Perform → Underperform |
| 2023-10-17 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
| 2023-09-27 | 開始されました | Mizuho | Buy |
| 2023-08-17 | アップグレード | Citigroup | Neutral → Buy |
| 2023-05-30 | 開始されました | William Blair | Outperform |
| 2023-04-13 | 開始されました | Cantor Fitzgerald | Overweight |
| 2023-03-21 | 開始されました | Bernstein | Mkt Perform |
| 2023-03-17 | 開始されました | Bryan Garnier | Buy |
| 2023-03-07 | 開始されました | Robert W. Baird | Neutral |
| 2022-10-11 | 開始されました | Morgan Stanley | Underweight |
| 2022-08-09 | ダウングレード | Barclays | Overweight → Equal Weight |
| 2022-06-23 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2022-06-17 | 開始されました | BMO Capital Markets | Outperform |
| 2022-04-28 | 開始されました | Credit Suisse | Neutral |
| 2021-12-07 | 開始されました | Cowen | Market Perform |
| 2021-10-19 | 開始されました | SVB Leerink | Outperform |
| 2021-06-14 | アップグレード | Citigroup | Sell → Neutral |
| 2021-04-21 | アップグレード | Jefferies | Hold → Buy |
| 2021-03-04 | 開始されました | JMP Securities | Mkt Outperform |
| 2020-12-10 | 繰り返されました | Chardan Capital Markets | Buy |
| 2020-12-10 | ダウングレード | Jefferies | Buy → Hold |
| 2020-12-10 | 繰り返されました | Needham | Buy |
| 2020-12-07 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2020-10-23 | 開始されました | RBC Capital Mkts | Sector Perform |
| 2020-10-05 | 開始されました | BofA Securities | Buy |
| 2020-07-28 | 繰り返されました | Needham | Buy |
| 2020-07-14 | 開始されました | SunTrust | Buy |
| 2020-06-15 | 繰り返されました | Canaccord Genuity | Buy |
| 2020-03-05 | 開始されました | Stifel | Hold |
| 2020-02-03 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2019-11-19 | アップグレード | William Blair | Mkt Perform → Outperform |
| 2019-11-12 | アップグレード | Oppenheimer | Perform → Outperform |
| 2019-08-01 | 開始されました | Jefferies | Buy |
| 2019-07-26 | 開始されました | Canaccord Genuity | Buy |
| 2019-06-10 | 開始されました | ROTH Capital | Buy |
| 2019-04-12 | 開始されました | Evercore ISI | Outperform |
| 2019-03-14 | 開始されました | William Blair | Mkt Perform |
| 2019-01-28 | ダウングレード | Goldman | Buy → Neutral |
| 2019-01-22 | ダウングレード | Citigroup | Neutral → Sell |
すべてを表示
Crispr Therapeutics Ag (CRSP) 最新ニュース
CRISPR Therapeutics AG (NASDAQ:CRSP) Shares Sold by Voloridge Investment Management LLC - MarketBeat
The Best Stocks to Invest $1,000 in Right Now - The Motley Fool
Capital Market Strategies LLC Buys 9,652 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat
Q2 EPS Forecast for CRISPR Therapeutics Increased by Analyst - MarketBeat
Insider Selling: CRISPR Therapeutics AG (NASDAQ:CRSP) Insider Sells 3,932 Shares of Stock - MarketBeat
Cas9 Technology Market Projected to Hit $30.4 Billion at a 19.81% CAGR by 2032 - industrytoday.co.uk
CRISPR Therapeutics AG (NASDAQ:CRSP) Shares Acquired by Green Alpha Advisors LLC - MarketBeat
The 2 Smartest Beaten-Down Biotech Stocks to Buy on the Dip - Yahoo Finance
Trading (CRSP) With Integrated Risk Controls - news.stocktradersdaily.com
Top 5 CRISPR Companies To Invest In (June 2025) - Securities.io
CRISPR Therapeutics AG (NASDAQ:CRSP) Shares Acquired by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC - MarketBeat
Zacks Research Has Positive Outlook for CRSP Q2 Earnings - Defense World
Two Sigma Advisers LP Buys 28,400 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat
CRISPR Therapeutics AG (NASDAQ:CRSP) Receives $71.75 Consensus Target Price from Analysts - MarketBeat
ARK Investment Expands Stake in Crispr Therapeutics (CRSP) | CRS - GuruFocus
ARK Investment Expands Stake in Crispr Therapeutics (CRSP) | CRSP Stock News - GuruFocus
Cathie Wood’s ARK Investment buys 294K shares of Crispr Therapeutics today - TipRanks
ARK Investment Increases Stake in Crispr Therapeutics (CRSP) | C - GuruFocus
CRISPR Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewswire
Two Sigma Investments LP Grows Stock Holdings in CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat
Crispr Therapeutics, Clover Health among healthcare stocks to join Russell 3000; INO, SAVA to exit - Seeking Alpha
CRISPR and Cas Genes Market Set to Witness Significant Growth - openPR.com
Cathie Wood’s ARK Investment buys 262K shares of Crispr Therapeutics today - TipRanks
Ameriprise Financial Inc. Acquires 18,412 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat
CRISPR Therapeutics AG (NASDAQ:CRSP) Given Average Recommendation of “Moderate Buy” by Brokerages - Defense World
Westwood Holdings Group Inc. Raises Stake in CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat
CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know - MSN
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Grows Stock Holdings in CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat
CRISPR Therapeutics' (CRSP) "Market Outperform" Rating Reiterated at JMP Securities - MarketBeat
CRISPR Therapeutics (NASDAQ:CRSP) Earns "Buy" Rating from HC Wainwright - MarketBeat
CRISPR Therapeutics’ SWOT analysis: gene-editing pioneer’s stock faces pivotal year - Investing.com Nigeria
Q2 EPS Estimate for CRISPR Therapeutics Decreased by Analyst - MarketBeat
Rafferty Asset Management LLC Lowers Holdings in CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat
Northern Trust Corp Has $10.12 Million Holdings in CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat
Cetera Investment Advisers Reduces Position in CRISPR Therapeutics AG (NASDAQ:CRSP) - Defense World
Q2 EPS Estimate for CRISPR Therapeutics Lowered by Analyst - Defense World
Transcript : CRISPR Therapeutics AG Presents at H.C. Wainwright 3rd Annual BioConnect Investor Conference 2025, May-20-2025 04 - marketscreener.com
Transcript : CRISPR Therapeutics AG Presents at RBC Capital Markets Global Healthcare Conference 2025, May-20-2025 10 - marketscreener.com
CRSP July 3rd Options Begin Trading - Nasdaq
CRISPR Therapeutics AG (NASDAQ:CRSP) Shares Sold by Lazard Asset Management LLC - MarketBeat
Ameriprise Financial Inc. Has $8.07 Million Holdings in CRISPR Therapeutics AG (NASDAQ:CRSP) - Defense World
(CRSP) Trading Report - news.stocktradersdaily.com
CRISPR Therapeutics AG (CRSP) Strikes $95M Deal with Sirius to Develop Blood Clot Drug - MSN
Crispr Therapeutics Ag (CRSP) 財務データ
収益
当期純利益
現金流量
EPS
Crispr Therapeutics Ag (CRSP) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Kulkarni Samarth | Chief Executive Officer |
Mar 21 '25 |
Sale |
41.23 |
10,031 |
413,578 |
195,085 |
| Bruno Julianne | Chief Operating Officer |
Mar 21 '25 |
Sale |
41.23 |
1,714 |
70,668 |
10,544 |
| Prasad Raju | Chief Financial Officer |
Mar 21 '25 |
Sale |
41.23 |
2,197 |
90,582 |
16,767 |
| KASINGER JAMES R. | General Counsel and Secretary |
Mar 21 '25 |
Sale |
41.23 |
3,185 |
131,318 |
81,729 |
| Prasad Raju | Chief Financial Officer |
Mar 17 '25 |
Sale |
41.80 |
3,762 |
157,252 |
12,714 |
| Kulkarni Samarth | Chief Executive Officer |
Mar 11 '25 |
Sale |
42.42 |
9,973 |
423,055 |
180,890 |
| Kulkarni Samarth | Chief Executive Officer |
Mar 12 '25 |
Sale |
43.32 |
4,462 |
193,294 |
185,428 |
| KASINGER JAMES R. | General Counsel and Secretary |
Mar 11 '25 |
Sale |
42.42 |
2,850 |
120,897 |
77,530 |
| KASINGER JAMES R. | General Counsel and Secretary |
Mar 12 '25 |
Sale |
43.32 |
1,116 |
48,345 |
78,664 |
| Bruno Julianne | Chief Operating Officer |
Mar 11 '25 |
Sale |
42.42 |
1,198 |
50,819 |
8,263 |
0.87%
0.19%
大文字化:
|
ボリューム (24 時間):